Skip to main content

Xyosted News

Testosterone Therapy Doesn't Increase Cancer Risk For Transmasculine People

FRIDAY, May 16, 2025 — Transmasculine and gender diverse people who use testosterone are not at an increased risk for cervical, ovarian or other gynecological cancers, a new study says. The results s...

FDA Medwatch Alert: FDA Alerts Customers to Voluntary Recall of Compounded Drugs Due to Sterility Issues by Drug Depot, LLC, dba APS Pharmacy

April 26, 2022 --FDA is alerting patients, health care professionals, veterinarians, and animal owners/caretakers about a voluntary recall by Drug Depot, LLC, doing business as APS Pharmacy, of...

FDA Approves Xyosted (testosterone enanthate) Injection for Testosterone Replacement Therapy in Adult Males

EWING, N.J., Oct. 01, 2018 (GLOBE NEWSWIRE) – Antares Pharma, Inc. (NASDAQ:ATRS) today announced the approval of Xyosted (testosterone enanthate) injection by the U.S. Food and Drug Administration...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Hypogonadism - Male

Xyosted patient information at Drugs.com